key: cord-0739785-58ovgdca authors: Ichinomiya, Taiga; Murata, Hiroaki; Sekino, Motohiro; Yokoyama, Haruka; Ogami-Takamura, Keiko; Higashijima, Ushio; Ashizawa, Nobuyuki; Izumikawa, Koichi; Machino, Ryusuke; Matsumoto, Keitaro; Nakaji, Shun; Yoshitomi, Osamu; Hara, Tetsuya title: Tracheobronchial stent insertion under veno-venous extracorporeal membrane oxygenation in a coronavirus disease 2019 patient date: 2021-09-10 journal: J Cardiothorac Vasc Anesth DOI: 10.1053/j.jvca.2021.09.009 sha: 6b935790ac56720fea7b8e1acdc83746646082d4 doc_id: 739785 cord_uid: 58ovgdca nan This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. We would like to thank Editage (www.editage.jp) for the English language editing. Keywords: SARS-CoV-2, Extracorporeal Membrane Oxygenation, Tracheal Neoplasms, Coronavirus disease 2019 (COVID-19) is a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus is highly infectious and is mainly transmitted from person to person via close contact and respiratory droplets. 1 Airborne transmission is an important route of infection, especially in cases where many droplets are generated. 2 Tracheobronchial stent placement is a relatively safe and effective treatment for tracheobronchial stenosis. The silicone stent insertion is typically performed via rigid bronchoscopy under general anesthesia with positive pressure ventilation. 3 However, this procedure requires high-frequency ventilation, and a large number of respiratory droplets are expelled due to air leakage from the side port used in rigid bronchoscopy during ventilation. Therefore, the risk of droplet transmission is extremely high during tracheobronchial stenting of patients with COVID-19. Extracorporeal membrane oxygenation (ECMO) is a useful technique for maintaining oxygenation and adequate ventilation while simultaneously removing carbon dioxide. However, it is conventionally considered a relative contraindication in patients with advanced malignancy due to a poor outcome despite ECMO. 4 ECMO is only used for high-risk patients with asphyxia who are difficult to manage under conventional ventilation during the tracheal stent placement. 5 In this report, we describe the case of a COVID-19 patient with an obstructive tracheal tumor that degenerated rapidly into respiratory failure. Silicone Y-tracheal stenting was performed under veno-venous ECMO (VV-ECMO) with general anesthesia. This method ensured oxygenation while also stopping ventilation and shortening the operation time to reduce the risk of SARS-Co-V-2 infection of the operating staff. Written informed consent for publication was obtained from the patient. A 59-year-old man (height 165 cm, weight 55 kg) with 2 years of dry cough was screened for COVID-19 due to close contact with a patient with COVID-19. The antigen test showed a positive result for SARS-CoV-2, and this prompted his hospitalization. At that time, computed tomography (CT) revealed a 40-mm tumor adjacent to the trachea, causing severe stenosis and right bronchial obstruction accompanied by right upper atelectasis. Radiological findings characteristic of COVID-19 were not found in the lung fields. On the same day, the patient's fever increased, and intravenous remdesivir and oral dexamethasone were administered due to the onset of suspected COVID-19 symptoms. However, oxygenation continued to gradually worsen, and mechanical ventilation through an orotracheal tube was initiated 6 days after the onset of symptoms. After starting ventilation, SpO 2 was 95% under FiO 2 at 80% and positive end-expiratory pressure (PEEP) was 5 cmH2O. High flow nasal oxygenation or non-invasive ventilation was not performed before mechanical ventilation. On the seventh day after his initial hospitalization, the patient was transferred to our hospital. Figure 1C ), they were not considered to be caused by SARS-CoV-2 infection. After discussion with a thoracic surgeon, infectious disease doctor, pulmonologist, cardiovascular surgeon, intensivist, and anesthesiologist, we concluded that the deterioration of the patient's respiratory condition was due to tracheal stenosis. We were concerned that the tumor had grown more rapidly and obstructed the trachea and bronchi, leading to asphyxia and making tracheal stenting difficult. Thus, we decided to perform tracheobronchial stent insertion immediately under general anesthesia with VV-ECMO. A positive result for SARS-CoV-2 via polymerase chain reaction (PCR) was confirmed just before the procedure. All staff in the operating room wore appropriate personal protective equipment (PPE) (N95 respirator mask, goggles, face mask, hair and foot coverings, hood, gown, and double gloves) throughout the procedure. General anesthesia was maintained using remimazolam 1.0 mg/kg/h, ultra-short-acting benzodiazepine, and remifentanil 0.5 µg/kg/min. Rocuronium, 7.0 µg/kg/min, was infused continuously to maintain a deep neuromuscular blockade. VV-ECMO was established before stenting. A 22Fr drainage cannula was introduced into the femoral vein and advanced at the junction between the inferior vena cava and the right atrium. A 16Fr reinjection cannula was introduced into the right internal jugular vein and advanced through the superior vena cava into the right atrium. A heparin-coated ECMO circuit was used without intravenous anticoagulants to reduce the risk of bleeding from the endotracheal tumor during the procedure. The activated partial thromboplastin time before the procedure was 30.2 seconds. After starting VV-ECMO, blood flow immediately reached 3.0-3.5 L/min (1.9-2.2 L/min/m 2 ), and the FiO 2 and outflow PaO 2 of VV-ECMO were 80% and 445 mmHg, respectively. Blood temperature was set at 35.5°C to reduce oxygen consumption. Dopamine and noradrenaline were infused to maintain adequate cardiac output and blood pressure, and patient hemodynamics were stable during VV-ECMO (blood pressure 115-135/65-70 mmHg and heart rate 85 bpm). The patient's hemoglobin was 13.8-15.3 g/dL; therefore, transfusion was not required. Mechanical ventilation was stopped, and the surgeons began the procedure after waiting for the end of exhalation (approximately 90 s) determined by end-tidal carbon dioxide. The tumor completely obstructed the right bronchi, and there was a lot of bleeding from the tumor. After careful suctioning of the blood, bougie and balloon dilations were used to relieve the bronchial obstruction under fiberoptic bronchoscopy guidance. Subsequently, a Dumon TM silicone Y-stent (Novatech, La Ciotat, France) was placed using rigid bronchoscopy. No lung ventilation was required throughout the procedure, and an antivirus filter was not connected to the rigid bronchoscope because of the likelihood of apnea during the procedure. SpO 2 was maintained between 88% and 94%. After stenting, tracheal intubation was performed using an 8.0 mm ID standard tube, and mechanical ventilation was restarted. TV was increased to approximately 500-550 mL (inspiratory pressure, 12 cmH 2 O), and the patient was successfully weaned from VV-ECMO. The time from asphyxia to completion of all procedures was 68 min. At ICU admission after surgery, mechanical ventilation settings were as follows: One indication for airway stenting is airway stenosis caused by endotracheal and extrinsic tumors. 6 Tracheobronchial stent insertion should be performed immediately if the patient's respiratory condition is exacerbated by tumor growth. Tracheobronchial stenting that requires open access to the airway is inherently accompanied by aerosol-generating procedures such as bag-mask ventilation, tracheal intubation/extubation, airway suctioning, high-frequency ventilation via the side port used in rigid bronchoscopy, and laser excision/ablation. Highfrequency ventilation via the side port used in rigid bronchoscopy causes a substantial amount of droplet and aerosol shedding due to air leakage around the rigid bronchoscope. Therefore, airway stenting for patients with COVID-19 bears an extremely high risk of infection for airway surgeons, anesthesiologists, and all other healthcare providers in the operating room. Theoretically, it may be best to postpone any kind of airway surgery in patients with COVID-19 until after the recovery of COVID-19 to avoid nosocomial infections among hospital staff. Indeed, according to several bronchology societies, bronchoscopy is relatively contraindicated in a patient with COVID-19. 7 In the present case, asymptomatic tracheobronchial stenosis on the verge of complete occlusion was fortuitously identified during the COVID-19 screening survey. It was uncertain how rapidly the tumor would grow to completely occlude the airway and when the infectivity of SARS-Co-V-2 would become negative. After a thorough multidisciplinary discussion, a decision was made to perform tracheobronchial stenting immediately. Based on chest CT findings, exacerbation of the respiratory condition was mainly due to the tracheobronchial stenosis that caused atelectasis, but not due to SARS-Co-V-2 infection. The survival rate after inserting tracheobronchial stents in patients with malignant airway disease has been reported to be only 3-4 months; the 1-year survival rate is 15%. 6.8 However, early discharge from the ICU and continued tumor therapy are independent predictors of survival time. 8 This may indicate that tumor therapy (radiation and/or chemotherapy) after immediate stent insertion prolongs patient survival. If we had waited for the patient to completely recover from COVID-19, it might have become impossible to place a stent due to further enlargement of the tumor. Additionally, rapid discharge from the ICU and weaning from mechanical ventilation after stent insertion help preserve medical resources, which has been imperative during the COVID-19 pandemic. Generally, silicone stents have some advantages over metallic stents for the management of malignant tracheal tumor. The patient with silicone stent can avoid recurrent obstruction by tumor ingrowth and allow radiation or chemotherapy to exert its effect. 9 Silicone stents can be removed if the size of the tumor reduces after the therapies. 10 Additionally, silicone stents can cover fistulas caused by radiation therapy or malignancy itself. 9 For these reasons, we chose silicone stent insertion in this case. However, rigid bronchoscopy under general anesthesia is required to insert a silicone stent, 9, 10 and the risk of a droplet and aerosol transmission is high during the procedure. ECMO is generally performed for severe acute respiratory distress syndrome (ARDS) in a patient with COVID-19 with poor oxygenation and hypercapnia. 11 Considering the respiratory condition, VV-ECMO was not an absolute necessity for stent insertion in this case. However, the use of VV-ECMO for stent insertion in a patient with COVID-19 has several benefits. First, although respiratory insufficiency in this patient was mainly caused by airway stenosis rather than ARDS caused by COVID-19, SARS-CoV-2 infection may also have been involved in the pathology, considering that oxygenation worsened rapidly in a short time. VV-ECMO ensured adequate oxygenation and carbon dioxide removal, increasing the safety of the stent insertion procedure. Second, the droplets and aerosols were expelled during ventilation, and it showed that aerosol-generating procedures, including short time manual ventilation before intubation, increase the risk of infection to health care workers. 12 Therefore, as a general rule, no ventilation will reduce the spread of droplets, thereby However, these are not general indications, and we decided it was better to insert a tracheal stent under planned VV-ECMO in this case with comprehensive judgment. As a limitation, in this case, the procedure was started after waiting for the end of exhalation determined by end-tidal carbon dioxide, but there was no scientific evidence whether this waiting period was enough to suppress the transmission. Normal speech generates thousands of oral droplets, which can be transmitted for over 10 minutes. 14 Additionally, it is recommended that the interventional room be cleaned 20 minutes after all aerosol-generating procedures to stabilize or disperse airborne droplets. 15 Thereby, it may be necessary to wait for a longer period than the end of exhalation determined by end-tidal carbon dioxide to suppress transmission, as was done in this case. However, the respiratory circuit with an antivirus filter was completely closed until the end of exhalation, and there was no ventilation during the procedure. Therefore, the risk of generating droplets or aerosols under the procedure condition was lesser than that under a ventilated condition. Lung ventilation can be necessary even when VV-ECMO is applied. To achieve complete respiratory support by VV-ECMO without lung ventilation, sufficient pump flow (>60 mL/kg/min) and low recirculation rate (ratio of ECMO blood flow to cardiac output >60%) are important. 16 As a judgment criterion for sufficient oxygenation, SaO 2 ≥80% is recommended during VV-ECMO management for adult respiratory failure. 4 If SaO 2 cannot be maintained under adequate pump flow, sedation, use of muscle relaxants and/or betablockers, and decreasing body temperature are recommended to suppress cardiac output and metabolic oxygen requirement. 16 Suppression of cardiac output can occasionally improve the ratio of ECMO blood flow to cardiac output. Fortunately, SaO 2 was maintained at approximately 90% in this case during the use of VV-ECMO. Therefore, we infused dopamine and noradrenaline to maintain adequate hemodynamics. In the present case, a deep muscular blockade by continuous rocuronium infusion helped avoid inadvertent spontaneous breathing or diaphragm contraction during the procedure. A heparin-coated ECMO circuit without anticoagulant use was useful in reducing the bleeding. Anticoagulants may exacerbate bleeding, which makes the procedure more difficult. Differential hypoxia is one of the problems during ECMO, and it can occur under veno-arterial-ECMO. In this case, VV-ECMO was set by a drainage cannula into the femoral vein and a reinjection cannula into the right internal jugular vein. Thus, it was not necessary to consider the possibility of differential hypoxia during the procedure. In conclusion, we described a successful case of intraoperative management of tracheobronchial stenting under VV-ECMO to treat tracheobronchial stenosis caused by a neoplasm in a patient with COVID-19. The indications for tracheobronchial stenting were carefully discussed from a multidisciplinary perspective. We minimized the risk of SARS-CoV-2 droplet transmission during the procedure by obtaining a non-breathing condition under VV-ECMO with general anesthesia. A) Coronal section image shows tracheobronchial stenosis via the neoplasm with right upper lobe atelectasis (white arrow). B) The diameter of the narrowest part of the trachea was 5 mm (black arrow). C) Transverse section image of the lung field shows localized ground-glass opacities. Practical considerations for performing regional anesthesia: lessons learned from the COVID-19 pandemic Ten scientific reasons in support of airborne transmission of SARS-CoV-2 Airway stents Extracorporeal Life Support Organization. ELSO Guidelines for Cardiopulmonary Extracorporeal Life Support Bronchotracheal stenting management by rigid bronchoscopy under extracorporeal membrane oxygenation (ECMO) support: 10 years of experience in a tertiary center Outcomes of tracheobronchial stents in patients with malignant airway disease Summarizing societal guidelines regarding bronchoscopy during the COVID-19 pandemic Tracheal stent placement provides opportunity for subsequent anti-cancer therapy for cancer patients with malignant respiratory complications Rigid bronchoscopy and silicone stents in the management of central airway obstruction Airway stenting Guidelines on the management of acute respiratory distress syndrome Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review Systematic review and meta-analysis of complications and mortality of veno-venous extracorporeal membrane oxygenation for refractory acute respiratory distress syndrome The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission Thoracic anesthesia of patients with suspected or confirmed 2019 novel coronavirus infection: preliminary recommendations for airway management by the European Association of Cardiothoracic Anaesthesiology Thoracic Subspecialty Committee Low blood arterial oxygenation during venovenous extracorporeal membrane oxygenation: proposal for a rational algorithm-based management